Literature DB >> 14585199

IFN-gamma-inducible chemokines enhance adaptive immunity and colitis.

Udai P Singh1, Shailesh Singh, Nuzhat Iqbal, Casey T Weaver, Jerry R McGhee, James W Lillard.   

Abstract

T helper type 1 (Th1) cells secreting interferon-gamma (IFN-gamma) have been closely associated with Crohn's disease (CD). Monokine-induced by IFN-gamma (MIG), IFN-gamma-inducible T cell alpha chemoattractant (I-TAC), and IFN-gamma-inducible protein-10 (IP-10), are chemokines that bind CXCR3 and mediate the chemotaxis of leukocytes. IP-10, MIG, and CXCR3 have been shown to be expressed at sites of CD. The current study stems from our recent findings that IP-10, MIG, and I-TAC significantly contribute to the development of Th1-mediated inflammatory responses. To better understand the role of CXCR3 interactions during CD, we characterized the effects of IP-10, MIG, I-TAC, and CXCR3+ T cells on mucosal immune responses. IP-10, MIG, and I-TAC significantly enhanced antigen-specific serum and mucosal antibodies through Th1-mediated events and CD28 modulation. Additionally, the adoptive transfer of naive CXCR3+ T cells and CD4+CD45RB(HI) to T cell receptor beta (TCRbeta) x delta(-/-) mice resulted in the onset of murine colitis. Taken together, these studies suggest that IP-10, MIG, I-TAC, and CXCR3 interactions are involved in mucosal immune responses required for the induction of CD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14585199     DOI: 10.1089/107999003322485099

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  28 in total

1.  Role of resveratrol-induced CD11b(+) Gr-1(+) myeloid derived suppressor cells (MDSCs) in the reduction of CXCR3(+) T cells and amelioration of chronic colitis in IL-10(-/-) mice.

Authors:  Udai P Singh; Narendra P Singh; Balwan Singh; Lorne J Hofseth; Dennis D Taub; Robert L Price; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Brain Behav Immun       Date:  2011-07-23       Impact factor: 7.217

2.  miR-155 deficiency protects mice from experimental colitis by reducing T helper type 1/type 17 responses.

Authors:  Udai P Singh; Angela E Murphy; Reilly T Enos; Haidar A Shamran; Narendra P Singh; Honbing Guan; Venkatesh L Hegde; Daping Fan; Robert L Price; Dennis D Taub; Manoj K Mishra; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

3.  An endogenous aryl hydrocarbon receptor ligand, ITE, induces regulatory T cells and ameliorates experimental colitis.

Authors:  Jessica D Abron; Narendra P Singh; Manoj K Mishra; Robert L Price; Mitzi Nagarkatti; Prakash S Nagarkatti; Udai P Singh
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-04-19       Impact factor: 4.052

4.  Cutting edge: IFN-γR signaling in non-T cell targets regulates T cell-mediated intestinal inflammation through multiple mechanisms.

Authors:  Jeong-su Do; Kewal Asosingh; William M Baldwin; Booki Min
Journal:  J Immunol       Date:  2014-02-12       Impact factor: 5.422

5.  Neuronal CXCL10 directs CD8+ T-cell recruitment and control of West Nile virus encephalitis.

Authors:  Robyn S Klein; Eugene Lin; Bo Zhang; Andrew D Luster; Judy Tollett; Melanie A Samuel; Michael Engle; Michael S Diamond
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

6.  Resveratrol (trans-3,5,4'-trihydroxystilbene) induces silent mating type information regulation-1 and down-regulates nuclear transcription factor-kappaB activation to abrogate dextran sulfate sodium-induced colitis.

Authors:  Udai P Singh; Narendra P Singh; Balwan Singh; Lorne J Hofseth; Robert L Price; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  J Pharmacol Exp Ther       Date:  2009-11-25       Impact factor: 4.030

7.  A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.

Authors:  W Reinisch; D W Hommes; G Van Assche; J-F Colombel; J-P Gendre; B Oldenburg; A Teml; K Geboes; H Ding; L Zhang; M Tang; M Cheng; S J H van Deventer; P Rutgeerts; T Pearce
Journal:  Gut       Date:  2006-02-21       Impact factor: 23.059

8.  CXCL10 expression and prognostic significance in stage II and III colorectal cancer.

Authors:  Zheng Jiang; Ye Xu; Sanjun Cai
Journal:  Mol Biol Rep       Date:  2009-10-10       Impact factor: 2.316

9.  VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma.

Authors:  Xinqi Wu; Anita Giobbie-Hurder; Xiaoyun Liao; Donald Lawrence; David McDermott; Jun Zhou; Scott Rodig; F Stephen Hodi
Journal:  Cancer Immunol Res       Date:  2016-08-22       Impact factor: 11.151

10.  Specificity tuning of antibody fragments to neutralize two human chemokines with a single agent.

Authors:  Séverine Fagète; Ulla Ravn; Franck Gueneau; Giovanni Magistrelli; Marie H Kosco-Vilbois; Nicolas Fischer
Journal:  MAbs       Date:  2009 May-Jun       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.